Ceftiofur Tazobactam 1125 mg injection in Veterinary PCD Franchise

Ceftiofur Tazobactam 1125 mg injection in Veterinary PCD Franchise

180 INR/Piece

Product Details:

  • Medicine Type Veterinary Injectables
  • Physical Form Powder
  • Ingredients Chemicals
  • Treatments & Functions Anti Biotic
  • Recommended For Pig Aquatic Animal Cattle Poultry Horse Sheep Goat Dogs Cats Pets Fowl
  • Quantity/Volume 0.001125 Kilogram(Kg)
  • Storage Instructions At Room Temperature
  • Click to View more
X

Ceftiofur Tazobactam 1125 mg injection in Veterinary PCD Franchise Price And Quantity

  • 1000 Piece
  • 180 INR/Piece

Ceftiofur Tazobactam 1125 mg injection in Veterinary PCD Franchise Product Specifications

  • Chemicals
  • 0.001125 Kilogram(Kg)
  • Powder
  • Pig Aquatic Animal Cattle Poultry Horse Sheep Goat Dogs Cats Pets Fowl
  • Anti Biotic
  • At Room Temperature
  • Veterinary Injectables

Ceftiofur Tazobactam 1125 mg injection in Veterinary PCD Franchise Trade Information

  • Cash in Advance (CID) Cash Advance (CA)
  • 100000 Piece Per Month
  • 1 Months
  • Sample costs shipping and taxes has to be paid by the buyer
  • Customize
  • Middle East Africa Asia
  • Dadra and Nagar Haveli Chandigarh Andaman and Nicobar Islands Uttarakhand Daman and Diu Lakshadweep Delhi Gujarat South India Central India East India West India Andhra Pradesh Assam Arunachal Pradesh Bihar Goa Haryana Jammu and Kashmir Jharkhand Kerala Madhya Pradesh Maharashtra Mizoram Meghalaya Manipur Pondicherry Rajasthan Sikkim Tamil Nadu Telangana Tripura West Bengal Nagaland Uttar Pradesh Karnataka North India Punjab Odisha Chhattisgarh Himachal Pradesh All India
  • GMP

Product Description

Ceftiofur sodium has demonstrated excellent in vitro and in vivo activity against Mannheimia haemolytica and Pasteurella multocida, two of the major pathogenic organisms associated with bovine respiratory disease (pneumonia, shipping fever). This drug has also demonstrated excellent in vitro and in vivo activity against Histophilus somni (Haemophilus somnus) and in vitro activity against Corynebacterium pyogenes, two other bacterial pathogens associated with bovine respiratory disease (BRD). Ceftiofur has demonstrated in vivo and in vitro activity against Fusobacterium necrophorum and Bacteroides melaninogenicus, two of the major pathogenic anaerobic bacteria associated with acute bovine interdigital necrobacillosis (foot rot, pododermatitis). Ceftiofur has excellent in vitro activity against Gram-negative pathogens such as Actinobacillus pleuropneumoniae, Salmonella choleraesuis, Pasteurella multocida and the Gram-positive pathogen Streptococcus suis, all of which singly or in combination can be associated with swine bacterial respiratory disease (swine bacterial pneumonia). Ceftiofur has also demonstrated excellent in vitro and in vivo activity against respiratory pathogens of horses. The drug was very active in vitro against Streptococcus zooepidemicus, S. equi, Streptococcus spp. and Pasteurella spp. isolated from patients with infections. Ceftiofur has demonstrated in vitro and in vivo activity against Mannheimia haemolytica, the major pathogenic bacterium associated with ovine respiratory disease (pneumonia). Ceftiofur has also demonstrated in vivo and in vitro activity against bacterial pathogens from dogs with urinary tract infections. Ceftiofur was more potent (in vitro) than other beta-lactam antibiotics against strains of Escherichia coli and Proteus mirabilisCeftiofur sodium has demonstrated excellent in vitro and in vivo activity against Mannheimia haemolytica and Pasteurella multocida, two of the major pathogenic organisms associated with bovine respiratory disease (pneumonia, shipping fever). This drug has also demonstrated excellent in vitro and in vivo activity against Histophilus somni (Haemophilus somnus) and in vitro activity against Corynebacterium pyogenes, two other bacterial pathogens associated with bovine respiratory disease (BRD). Ceftiofur has demonstrated in vivo and in vitro activity against Fusobacterium necrophorum and Bacteroides melaninogenicus, two of the major pathogenic anaerobic bacteria associated with acute bovine interdigital necrobacillosis (foot rot, pododermatitis). Ceftiofur has excellent in vitro activity against Gram-negative pathogens such as Actinobacillus pleuropneumoniae, Salmonella choleraesuis, Pasteurella multocida and the Gram-positive pathogen Streptococcus suis, all of which singly or in combination can be associated with swine bacterial respiratory disease (swine bacterial pneumonia). Ceftiofur has also demonstrated excellent in vitro and in vivo activity against respiratory pathogens of horses. The drug was very active in vitro against Streptococcus zooepidemicus, S. equi, Streptococcus spp. and Pasteurella spp. isolated from patients with infections. Ceftiofur has demonstrated in vitro and in vivo activity against Mannheimia haemolytica, the major pathogenic bacterium associated with ovine respiratory disease (pneumonia). Ceftiofur has also demonstrated in vivo and in vitro activity against bacterial pathogens from dogs with urinary tract infections. Ceftiofur was more potent (in vitro) than other beta-lactam antibiotics against strains of Escherichia coli and Proteus mirabilisCeftiofur sodium has demonstrated excellent in vitro and in vivo activity against Mannheimia haemolytica and Pasteurella multocida, two of the major pathogenic organisms associated with bovine respiratory disease (pneumonia, shipping fever). This drug has also demonstrated excellent in vitro and in vivo activity against Histophilus somni (Haemophilus somnus) and in vitro activity against Corynebacterium pyogenes, two other bacterial pathogens associated with bovine respiratory disease (BRD). Ceftiofur has demonstrated in vivo and in vitro activity against Fusobacterium necrophorum and Bacteroides melaninogenicus, two of the major pathogenic anaerobic bacteria associated with acute bovine interdigital necrobacillosis (foot rot, pododermatitis). Ceftiofur has excellent in vitro activity against Gram-negative pathogens such as Actinobacillus pleuropneumoniae, Salmonella choleraesuis, Pasteurella multocida and the Gram-positive pathogen Streptococcus suis, all of which singly or in combination can be associated with swine bacterial respiratory disease (swine bacterial pneumonia). Ceftiofur has also demonstrated excellent in vitro and in vivo activity against respiratory pathogens of horses. The drug was very active in vitro against Streptococcus zooepidemicus, S. equi, Streptococcus spp. and Pasteurella spp. isolated from patients with infections. Ceftiofur has demonstrated in vitro and in vivo activity against Mannheimia haemolytica, the major pathogenic bacterium associated with ovine respiratory disease (pneumonia). Ceftiofur has also demonstrated in vivo and in vitro activity against bacterial pathogens from dogs with urinary tract infections. Ceftiofur was more potent (in vitro) than other beta-lactam antibiotics against strains of Escherichia coli and Proteus mirabilis
Enter Buying Requirement Details
Email Id
Mobile number

Other Products in 'Veterinary PCD Injections' category



Back to top